S-OA-A
Oral Abstracts - Session A - Allogeneic Transplants
BMT Tandem "Scientific" Meeting
Texas B (Gaylord Texan)
Chairs:
Paul V. O'Donnell, MD, PhD
and
David L. Porter, MD
Disclosures:
P. V. O'Donnell,
Nothing To Disclose
D. L. Porter,
Novartis, Patent holder, research support: Intellectual Property Rights, Research Funding and Royalty
Genentech, Spouse employment: Salary
Effect of Antithymocyte Globulin Source on Outcomes of Bone Marrow Transplantation for Severe Aplastic Anemia
Joseph H. Antin, MD, Dana Farber Cancer Institute;
H Joachim Deeg, MD, Fred Hutchinson Cancer Research Center;
Sandra Korman, Medical College of Wisconsin;
Carmem Bonfim, MD, Federal University of Parana;
Ryotaro Nakamura, MD, City of Hope;
Mary M. Horowitz, MD, MS, CIBMTR and Medical College of Wisconsin;
Daniel J. Weisdorf, MD, University of Minnesota;
Mary Eapen, MBBS, MS, CIBMTR/Medical College of Wisconsin;
Michael A. Pulsipher, MD, Primary Children's Medical Center, University of Utah School of Medicine
Iron Overload in Allogeneic Stem Cell Transplantation Outcome: A Meta-Analysis
Philippe Armand, MD, PhD, Dana-Farber Cancer Institute;
Haesook T Kim, PhD, Dana-Farber Cancer Institute;
Johanna Virtanen, MD, Turku University Hospital;
Maija Itälä-Remes, MD, Turku University Hospital;
Navneet S. Majhail, MD, MS, Cleveland Clinic Foundation;
Linda J. Burns, MD, University of Minnesota;
Todd Defor, MS, University of Minnesota;
Bryan Trottier, MD, University of Minnesota;
Uwe Platzbecker, MD, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Joseph H Antin, MD, Dana-Farber Cancer Institute;
Martin Wermke, MD, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
Less Acute Graft-Versus-Host Disease with Higher Mycophenolate Dose in Double Umbilical Cord Blood Transplant Recipients
Nelli Bejanyan, MD, University of Minnesota;
John Rogosheske, PharmD, University of Minnesota Medical Center, Fairview;
Todd Defor, MS, University of Minnesota;
Kelli Esbaum, PharmD, University of Minnesota Medical Center;
Mukta Arora, MD, MS, University of Minnesota;
Margaret L. MacMillan, MD, MSc, University of Minnesota;
John E. Wagner, MD, University of Minnesota;
Daniel J. Weisdorf, MD, University of Minnesota;
Pamala Jacobson, PharmD, University of Minnesota;
Claudio Brunstein, MD, PhD, University of Minnesota
T-Cell Replete Peripheral Blood Stem Cell Transplantation after Non-Myeloablative Conditioning with Post-Transplant High Dose Cyclophosphamide Is Safe and Is Associated with Acceptable Outcomes
Pavan Kumar Bhamidipati, Washington University School of Medicine;
John F. DiPersio, MD, PhD, Washington University School of Medicine;
Keith Stockerl-Goldstein, Washington University School of Medicine;
Geoffrey L. Uy, MD, Washington University School of Medicine;
Peter Westervelt, MD, PhD, Washington University School of Medicine;
Feng Gao, Washington University School of Medicine;
Ravi Vij, MD, Washington University School of Medicine;
Mark A. Schroeder, MD, Washington University School of Medicine;
Camille Abboud, MD, Washington University School of Medicine;
Iskra Pusic, MD, Washington University Medical Center;
Rizwan Romee, MD, Washington University School of Medicine
Plasma and Intracellular Population Pharmacokinetic Analysis of Fludarabine in Pediatric Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients
Janel Long-Boyle, PharmD, PhD, UCSF;
Nancy Sambol, PharmD, UCSF;
Christopher C. Dvorak, MD, University of California San Francisco Medical Center;
Morton J Cowan, MD, UCSF Benioff Children's Hospital;
Shirley Lee, PharmD, UCSF;
Liusheng Huang, PhD, UCSF;
Biljana Horn, MD, UCSF Benioff Children's Hospital;
Melisa Stricherz, PharmD, University of Minnesota Amplatz Children's Hospital;
Jakub Tolar, MD, PhD, University of Minnesota;
Paul Orchard, MD, University of Minnesota;
Pamala Jacobson, PharmD, University of Minnesota;
Francesca Aweeka, PharmD, UCSF
Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (AlloPBHCT) with TBI-Based Conditioning Regimens
Michael Burns, BA, Roswell Park Cancer Institute;
Anurag Singh, MD, Roswell Park Cancer Institute;
Yali Zhang, MPH, Roswell Park Cancer Institute;
George L Chen, MD, Roswell Park Cancer Institute;
Hong Liu, MD, PhD, Roswell Park Cancer Institute;
Maureen Ross, MD, PhD, Roswell Park Cancer Institute;
Philip L. McCarthy, MD, Roswell Park Cancer Institute;
Theresa Hahn, PhD, Roswell Park Cancer Institute
Sequence of Cyclophosphamide (Cy) and Total Body Irradiation (TBI) Prior to Hematopoietic Cell Transplant (HCT) for Patients with Acute Leukemia: Impact upon Complications and Patient Outcome
Jennifer L. Holter-Chakrabarty, MD, University of Oklahoma;
Mei-Jie Zhang, PhD, Medical College of Wisconsin;
Xiaochun Zhu, MS, Medical College of Wisconsin;
Görgun Akpek, MD, MHS, Banner MD Anderson Cancer Center;
Mahmoud D. Aljurf, MD, MPH, King Faisal Specialist Hospital and Research Centre;
Andrew S. Artz, MD, MS, University of Chicago Hospitals;
Frédéric Baron, MD, PhD, University of Liège, GIGA-I3;
Amber M. Borden, MD, University of Oklahoma;
Christopher N. Bredeson, MD, MSc, The Ottawa Hospital Blood & Marrow Transplant Program;
Christopher C. Dvorak, MD, University of California San Francisco Medical Center;
Robert B. Epstein, MD, University of Oklahoma;
Hillard M. Lazarus, MD, University Hospitals Case Medical Center;
Richard Olsson, MD, PhD, MMSc, Karolinska University Hospital;
Namali Pierson, MD, University of Oklahoma;
George B. Selby, MD, University of Oklahoma;
Kirsten M. Williams, MD, National Cancer Institute, NIH;
Kenneth R. Cooke, MD, Johns Hopkins University;
Marcelo C. Pasquini, MD, MS, CIBMTR/Medical College of Wisconsin;
Philip L. McCarthy, MD, Roswell Park Cancer Institute
